
    
      This is a single arm Phase II study of adjuvant radiation for locally-advanced p16+
      oropharyngeal squamous cell carcinoma. Patients with pT0-T3, N0-N2b, M0 disease (per AJCC 7th
      ed) with <5 positive lymph nodes, will be eligible. Patients will have undergone TORS primary
      site resection and ipsilateral neck dissection. Patients will undergo radiation dose
      reduction and target volume reduction.
    
  